Clinical trials
Bladder Cancer Recurrence clinical trials
Below are recruiting bladder cancer recurrence clinical trials, each written for real people, not researchers. We’re tracking 158 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06503614RecruitingPhase 2
Durvalumab plus monalizumab for non-invasive bladder cancer
This study tests two immunotherapy drugs (durvalumab and monalizumab) in people with a type of bladder cancer that hasn't spread into the deep muscle layer. The goal is to see if this combination can help control the cancer and prevent it from coming back, possibly avoiding the need for bladder removal.
San Francisco, CaliforniaAges 18 years+ - NCT06337942Recruiting
Bladder or kidney-bladder transplant from a deceased donor
This trial offers a first-in-human transplant of a bladder or a kidney combined with a bladder from a deceased donor. It is for people with severe bladder problems or bladder cancer who already need a new bladder or are on immune-suppressing medicines for a prior organ transplant.
Los Angeles, CaliforniaAges 18–70 - NCT06644846Recruiting
Spaced radiation for gynecologic cancers
This trial tests a special type of radiation that is given in small, spaced-out beams to treat gynecologic cancers (like cervical or uterine cancer). It is for patients who cannot get standard internal radiation (brachytherapy) because of unusual anatomy, large tumors, a narrow vagina, or anesthesia risks.
Navi Mumbai, MaharashtraAges 18–70 - NCT05962541RecruitingPhase 4
Using bladder scans to plan repeat surgery for bladder cancer
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
Rome, LazioAges 18 years+ - NCT05521698RecruitingPhase 1
Bicalutamide for early-stage bladder cancer
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Tucson, ArizonaAges 18 years+ - NCT07087860RecruitingPhase 2
Plasma exchange plus targeted therapy for advanced bladder cancer
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
Rochester, MinnesotaAges 18 years+ - NCT05646550RecruitingPhase 1
Antibody CC-1 for men with returning prostate cancer
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
TübingenAges 18 years+ - NCT07038928Recruiting
Treatment patterns and markers in bladder cancer in Russia
This study looks at how bladder cancer is treated and what biological markers are present in patients in Russia. If you join, you may help doctors learn more about which treatments work best based on your tumor type.
ArkhangelskAges 18 years+ - NCT07019220RecruitingPhase 2
Chemoablation for low-risk bladder cancer
This trial tests using chemotherapy directly into the bladder to treat low-grade bladder cancer that has come back, as an alternative to surgery. It may help people with small, low-grade tumors avoid the need for a more invasive procedure.
ViennaAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07286240RecruitingPhase 2
QL1706 with chemo and anlotinib for recurrent ovarian cancer
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
Guangzhou, GuangdongAges 18–70 - NCT04900558Recruiting
Study outcomes after robotic bladder removal surgery
This trial follows adults who are planning to have a robotic radical cystectomy (surgery to remove the bladder and surrounding tissue) to learn what outcomes to expect. If you choose to join and meet the basics, it may help your team compare results and improve care for future patients.
Florence, TuscanyAges 18 years+ - NCT07686380RecruitingPhase 2
IL-15 treatment with or without vaccine for prostate cancer
This trial tests a drug called IL-15 superagonist (with or without a vaccine) for men whose prostate cancer has come back (shown by rising PSA) after they already had targeted radiation therapy. The goal is to see if this treatment can lower or control PSA levels.
Bethesda, MarylandAges 18–120 - NCT07297004RecruitingPhase 2
Targeted radiation for recurrent rectal cancer
This trial tests targeted radiation (SBRT) for people whose rectal cancer has come back in the pelvis and cannot be surgically removed. The goal is to see if this focused radiation can control the tumor with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT04947059RecruitingPhase 3
Stop bladder cancer coming back with medicine after bladder surgery
This trial tests whether putting chemotherapy medicine directly into the bladder right after surgery helps prevent bladder cancer from coming back. It compares gemcitabine versus epirubicin given as an immediate bladder “wash-in.”
Larissa, Larissa/ThessalyAges 18–100 - NCT07749924Recruiting
Watchful waiting vs. bladder chemotherapy for intermediate-risk bladder cancer
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
DaqingAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Birmingham, AlabamaAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Tucson, ArizonaAges 18 years+ - NCT06245603Recruiting
Testing Hydeal Cyst with standard treatment for bladder cancer
This study tests a bladder instillation called Hydeal Cyst, given alongside standard BCG or MMC therapy, to see if it helps reduce side effects or improve outcomes for people with non-muscle invasive bladder cancer.
BergamoAges 18 years+ - NCT05656235RecruitingPhase 2
Study of keeping kidneys longer in upper tract bladder cancer
This Phase 2 trial studies whether a combination treatment can control high-grade upper tract urothelial cancer without removing the kidney and ureter (radical nephroureterectomy). It may help people who must avoid surgery or choose not to have it because of medical risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05002556Recruiting
Bladder cancer follow-up registry for adults in France
This trial is a real-world registry that collects information during follow-up for certain early-stage bladder cancer. It may help doctors understand how urinary test results relate to recurrence and guide monitoring over time.
Aix-en-ProvenceAges 18 years+ - NCT06929286RecruitingPhase 3
Gene therapy vs standard care for bladder cancer after BCG fails
This trial compares a gene therapy (nadofaragene firadenovec) against standard care for people with an early-stage bladder cancer that has not responded to BCG. The goal is to see if this treatment is more effective and possibly helps avoid bladder removal.
Baltimore, MarylandAges 21 years+ - NCT05231655Recruiting
Study testing fresh tumor tissue from cancer surgery or biopsy
This study collects fresh samples of tumor tissue during procedures like surgery, biopsy, or TURBT to test a cancer therapy outside the body. It may help researchers learn which treatments work better for different solid cancers.
Sheffield, South YorkshireAges 16 years+
Hear when a new Bladder Cancer Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bladder cancer recurrence?
- Yes. Clin2 currently lists 158 recruiting bladder cancer recurrence studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bladder cancer recurrence trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bladder cancer recurrence trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.